Latest fiscal year 2022 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2022, PASITHEA THERAPEUTICS CORP. reported revenue of $0M, up 3130.4% year over year. Operating margin was -2587.3% and net margin -2864.3%, on a free-cash-flow margin of -3014.8% with capital expenditure at 22.0% of revenue. Every figure is computed directly from KTTA's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2022 | $0M | -2587.3% | -2864.3% |
| FY2021 | $0M | -29925.7% | -14430.5% |
How does KTTA compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.